Galmed Pharmaceuticals Ltd. financial data

Symbol
GLMD on Nasdaq
Location
Ramat Gan, Israel
Fiscal year end
31 December
Latest financial report
6-K - Q3 2025 - 26 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -48% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,654,428 shares -67%
Common Stock, Shares, Outstanding 5,479,231 shares
Common Stock, Value, Issued $2,786,000 USD
Weighted Average Number of Shares Outstanding, Basic 5,460,476 shares 558%
Weighted Average Number of Shares Outstanding, Diluted 5,460,476 shares 558%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,086,000 USD 47%
General and Administrative Expense $1,009,000 USD -21%
Net Income (Loss) Attributable to Parent $8,700,000 USD 1.1%
Earnings Per Share, Basic 0.33 USD/shares -86%
Earnings Per Share, Diluted 0.33 USD/shares -86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,314,000 USD
Marketable Securities, Current $8,177,000 USD
Assets, Current $19,724,000 USD
Other Assets, Noncurrent $267,000 USD
Assets $21,584,000 USD
Accounts Payable, Current $1,674,000 USD
Liabilities, Current $2,472,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $316,000 USD
Retained Earnings (Accumulated Deficit) $205,960,000 USD
Stockholders' Equity Attributable to Parent $19,112,000 USD 3.7%
Liabilities and Equity $21,584,000 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 900,000,000 shares
Common Stock, Shares, Issued 5,479,231 shares
Common Stock, Par or Stated Value Per Share 1.8 USD/shares
Operating Lease, Liability $0 USD -100%
Property, Plant and Equipment, Gross $1,103,000 USD 0.09%
Additional Paid in Capital $222,602,000 USD